Biovie Inc (BIVI NASDAQ) stock market data APIs
$1.837
0.02(1.1%)
as of September 17, 2025
Try our APIs with
free plan!
Biovie Inc Financial Data Overview
Price chart is built with
Anychart
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Prev. Close
1.837
Open
1.8615
High
1.9425
Low
1.837
52 wk Range
1.42-44.8
Market Cap
13 825 K
Shares Outstanding
7 534 K
EPS
-11.05
Beta
0.857
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biovie Inc data using free add-ons & libraries
Get Biovie Inc Fundamental Data
Biovie Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -17 836 824
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-15
- EPS/Forecast: -3.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biovie Inc News
New
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological an...
Unusual volume stocks in Monday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT AUUD [https://www.c...
Top stock movements in today's session.
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS...
Biovie stock plunges after pricing $12 million public offering
Investing.com -- Biovie Inc (NASDAQ:BIVI) stock plunged 43% after the clinical-stage biopharmaceutical company announced the pricing of a $12 million underwritten public offering. The offering cons...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
